www.BioNJ.org 1:00 p.m. – 1:30 p.m. Registration & Networking 1:30 p.m. – 1:45 p.m. Welcome & Opening Remarks • Debbie Hart, President & CEO, BioNJ • Michael Malz, Executive Director, Morgan Stanley • Emilio Ragosa, Managing Partner, DLA Piper 1:45 p.m. – 2:15 p.m. Industry Overview by Mark Parsonson, Executive Director, Pharma Services Investment Banking, Morgan Stanley Mark will discuss trends in AI and digital health and how they are transforming the biopharma industry. 2:20 p.m. – 2:45 p.m. Lightning Pitches 90-second introductions by companies using AI or digital health innovations to change the healthcare industry: 2:45 p.m. – 3:15 p.m. Networking Break & Help Desks Network with attendees and speakers; plus, schedule a time to meet one-on-one with representatives at our Industry Help Desks, including: • Hackensack Meridian Health • Morgan Stanley • New Jersey Economic Development Authority • Tech Council Ventures 3:15 p.m. – 4:15 p.m. Panel: AI and Digital Health – The Bottom Line for Patients A panel of thought leaders will discuss how AI and digital health are impacting each of their respective areas, and how that translates to better drugs, better care and increased efficiencies across the biopharma and healthcare systems. Panelists: • Jeevan Duggempudi, Partner, AI & Analytics, IBM • Suhas Krishna, Vice President & Head, Product Management Digital Health, Bristol Myers Squibb • Anjan Roy, Managing Director, Life Sciences AI & Data, Deloitte • Sameer Sethi, Senior Vice President, Chief Data & Analytics Officer, Hackensack Meridian Health • Danny Tobey, M.D., Chair, AI Practice, DLA Piper Moderator: • Bethany Hills, Partner, Vice Chair, FDA Practices, DLA Piper 4:20 p.m. – 4:40 p.m. AI/Digital Health Company Spotlight: Teva Pharmaceuticals Navigating the Path to Digital Therapeutics Adoption Presented by Anna Sandler, Head of Digital Health Marketing – Global and U.S., Teva Pharmaceuticals 4:45 p.m. – 4:55 p.m. Closing Remarks • Debbie Hart, President & CEO, BioNJ • David Fritz, Regional Managing Director, Morgan Stanley • Emilio Ragosa, Managing Partner, DLA Piper 4:55 p.m. – 6:00 p.m. Networking Reception Enjoy beverages and hors d’oeuvres while you network with members of the BioNJ Entrepreneur Ecosystem. AI & DIGITAL HEALTH DAY AGENDA NOVEMBER 1, 2023 1 • Curio • HopeAI, Inc. • Iktos • JOGO Health • Kolate.AI • Lura Health • MARCo Health Inc. • Navierre • PharmaNest • SciMar One • tenXclinical • Vital Start Health
SPEAKERS www.BioNJ.org 4 2 Jeevan Duggempudi, Partner, AI & Analytics, IBM Mr. Duggempudi is a Partner within the Healthcare and Life Sciences Practice at IBM Consulting. He is passionate about applying data and AI to make a step change improvement in business operations. Throughout his career, Mr. Duggempudi has delivered Data and AI business transformation programs with the aim of reducing costs, increasing revenue, driving automation and managing risks. Mr. Duggempudi has partnered with life sciences and healthcare companies to envision, develop, deploy and commercialize solutions in the areas of Patient-centric Digital Health, Medication Adherence, Commercial Forecasting, RWE, Population Health, Lifestyle-Based analytics, Cognitive Customer Care, Modern Data Platforms, Content Intelligence and Generative AI. David Fritz, Regional Managing Director, Morgan Stanley Mr. Fritz is Managing Director and leader of the Central New Jersey Complex at Morgan Stanley Wealth Management. Following a career in the military, Mr. Fritz began his career in financial services as a Financial Advisor at PaineWebber in 1996. In 2005, Mr. Fritz assumed the supervisory role as Complex Manager in Sacramento, CA, where he worked for 10 years before being appointed to Complex Manager for the newly formed Central New Jersey region which is among the largest in the NY/NJ marketplace. Debbie Hart, President & CEO, BioNJ Ms. Hart worked alongside New Jersey’s biopharmaceutical industry leaders to establish BioNJ in 1994. Dedicated to BioNJ’s mission to help our Members help Patients, Ms. Hart is recognized as a respected thought leader and influential advocate. Under Ms. Hart’s leadership, BioNJ has become the trusted voice of the life sciences industry in New Jersey – working directly with legislative leaders in both Trenton and Washington D.C. to advance the life sciences industry, foster medical innovation and Patient access, while ensuring health equity and healthcare affordability. Most recently, she was named by Governor Murphy as the Chair of the New Jersey Commission on Science, Innovation and Technology. Bethany Hills, Partner, Vice Chair, FDA Practices, DLA Piper Ms. Hills focuses her practice on life sciences and healthcare. She advises clients on the full range of regulatory compliance issues, bringing together FDA regulatory, healthcare regulatory and life sciences compliance expertise. Ms. Hills helps her clients manage complex, multi-faceted regulatory compliance issues in product development, product launch, ongoing market compliance and defends private and government enforcement actions. She helps companies manage strategic and critical regulatory compliance issues impacting product development and classification, governmental inspections and investigations, and complex regulatory business challenges, such as product approvals and labeling, and collaborative research, supply and distribution. Pavita Howe, Vice President, Innovation and Entrepreneurship, BioNJ Prior to BioNJ, Ms. Howe served as Director of Entrepreneurship Partnerships at Rutgers University, where she worked with internal and external partners to grow Rutgers’ entrepreneurial ecosystem, bring visibility to Rutgers affiliated start-ups and connect them to valuable resources at the university and across the broader New Jersey entrepreneurial network. In addition, Ms. Howe worked with start-ups in the Rutgers community who were bringing innovations to market in a variety of industries, including life sciences, healthcare, technology, digital health, food and agriculture and climate/sustainability technologies. Prior to Rutgers, Ms. Howe spent her career working in marketing and leadership roles at start-ups in California and New Jersey.
SPEAKERS www.BioNJ.org 3 Suhas Krishna, Vice President & Head, Product Management Digital Health, Bristol Myers Squibb Mr. Krishna leads a group responsible for the process of planning, developing and successfully executing digital health products for BMS from initiation to launch. He previously served as Head of Digital Health for BMS’s Worldwide Commercialization organization, where he was responsible for Digital Health strategy and implementation for Global Commercialization across BMS therapeutic areas. Mr. Krishna has over 20 years of experience in the pharmaceutical and medical device industry and has delivered 25+ novel medical devices or combination products from concept to global commercialization and has 14+ patents that are either issued or filed worldwide. Prior to BMS, Mr. Krishna served as the Global Head of Technical Operations at Merck & Co. Michael Malz, Executive Director, Morgan Stanley Mr. Malz’s practice is built on the principles of honesty, trust, attention to detail and commitment to client goals. These core beliefs remain the foundation of his practice today. After years of supporting 401(k) plans, Mr. Malz was awarded the distinguished Corporate Retirement Director (CRD) designation within Morgan Stanley, which is held by less than 2% of the financial advisors in the firm. The CRD designation recognizes advisors who have dedicated their practice to helping corporate clients manage all aspects of their retirement plans. Mr. Malz’s works with Plan Sponsors, Trustees and Investment Committees to assist them in managing their fiduciary duties. Mark Parsonson, Executive Director, Pharma Services Investment Banking, Morgan Stanley Mr. Parsonson is a senior member of the Morgan Stanley Healthcare Investment Banking team with a focus on pharma services, including the increasing intersection of technology and biopharma in driving innovation in drug development and commercialization. Mr. Parsonson has a BSc in Economics from the London School of Economics & Political Science and an MBA from Columbia Business School and is a CFA Charterholder. Emilio Ragosa, Managing Partner, DLA Piper Mr. Ragosa counsels clients on securities offerings, mergers and acquisitions and venture capital transactions. His practice focuses on clients within the life sciences and technology industries. Mr. Ragosa’s clients include private and public companies, as well as venture capital firms, private equity firms, family offices and underwriters. His experience makes him uniquely capable of advising clients from formation through capital raising until a sale or IPO. Mr. Ragosa also serves as the Managing Partner for DLA’s New Jersey offices. Anjan Roy, Managing Director, Life Sciences AI & Data, Deloitte Mr. Roy has over 25 years of consulting experience and is proficient in planning, architecting, designing, developing and implementing complex AI and Data capabilities for life sciences organizations. He leads Deloitte’s Life Sciences Commercial Analytics and Information Management capability. Mr. Roy’s core competencies include complex data integration, data architecture, information strategy and business analytics. He has also successfully led multiple strategy and implementation engagements at various leading pharmaceutical and biotech clients enabling them to become insights driven leveraging data and information.
SPEAKERS www.BioNJ.org 4 Anna Sandler, Head, Digital Health Marketing, Global and U.S., Teva Pharmaceuticals Ms. Sandler is responsible for U.S. and Global Digital Health business focused on DIGIHALER franchise, including go-to-market models, commercial blueprint and implementation and strategic alignment for evidence generation. She and her team are working on making innovative DIGIHALER capabilities available and known to Patients, health care providers, IDNs and technology platform partners in U.S. She is also leading the global planning and rollout of the DIGIHALER platform. Ms. Sandler joined Teva Pharmaceuticals in 2019 as a Head of U.S. Specialty Insights. Before Teva Pharmaceuticals, Ms. Sandler held leadership positions at Sanofi, where she worked in a variety of commercial roles, driving growth for a range of portfolios. Sameer Sethi, Senior Vice President, Chief Data & Analytics Officer, Hackensack Meridian Health Mr. Sethi is a seasoned leader and expert in healthcare data and analytics with a proven track record of enabling use of data and analytical techniques to drive distinctiveness and deliver transformative impact. He has focused his career on data, technology and innovation for healthcare providers. His experiences in data and analytics roles across consulting and health systems gives him diverse perspectives on the challenges facing providers in data and insights enablement and technology adoption. Mr. Sethi and his team are currently focused on accelerating the use of Artificial Intelligence (AI) and Machine Learning (ML) to deliver high quality, affordable, more accessible and more efficient healthcare. Danny Tobey, M.D., Chair, AI Practice, DLA Piper Dr. Tobey is a medical doctor and software entrepreneur who represents life sciences, technology and healthcare clients in a variety of regulatory and litigation matters involving FDA, CDC, HHS, CMS, private payers and tort and commercial litigants. Dr. Tobey leads Insider’s 2022 list of top lawyers helping companies adopt artificial intelligence (AI) and leads the firm’s team helping companies navigate the legal landscape of emerging and disruptive technologies, including AI and data science. The Library of Congress gave Dr. Tobey a Burton Award recognizing “the best of the best writers in the legal profession” among the nation’s top 1,000 largest law firms.
LIGHTNING PITCHES www.BioNJ.org 5 Presenter: Shailja Dixit, CEO | [email protected] Curio Digital Therapeutics (“Curio”) develops comprehensive, digital behavioral health solutions for women across the cycle of life. Our flagship program, MamaLift, is a Class I General Wellness device. MamaLift is intended to help women reduce their risk of anxiety and depression during pregnancy or after delivery. Curio is an early stage company, pre-revenue, in Series A. Presenter: Philip Laut, Vice President & Head of U.S. Sales, Business Development & Operations | [email protected] Iktos develops innovative Artificial Intelligence technologies based on deep learning generative algorithms to accelerate drug discovery projects (from hit-discovery through hit-to-lead to lead optimization). We sell SAAS as a software but also provide services and/or collaborations — utilizing the strong teams we have in medicinal chemistry, computational chemistry and date sciences. Iktos can help during the entire DMT cycle (design/make/test), including robotics to validate what is designed. Presenter: Sanjai Murali, Founder & CEO | [email protected] JOGO uses wearable sensors and an AI-driven mobile app to provide virtual treatments for neuromuscular dysfunctions in chronic stroke, pelvic floor disorders, chronic pain and tremors by tapping into the natural neuroplasticity of the central nervous system (CNS). JOGO treatments are delivered via JOGO’s own virtual clinic and through a network of partner providers. JOGO is FDA 510K exempted and reimbursed by Medicare and most commercial payers. Mayo Clinic is a strategic partner and an investor, developing early detection and treatments for essential, functional and Parkinsonian tremors. Co-founder’s previous AI venture was acquired by IQVIA. Presenter: Will Ma, Founder & CEO | [email protected] We are creating an AI copilot for clinical trials to bring new treatments to Patients faster. The AI copilot works alongside the clinical development team, such as clinicians and statisticians, to optimize the trial design, accelerate the timeline and reduce the cost. Our initial product, focusing on clinical insights in multiple myeloma, is ready for test use. Starting with one indication, we foresee expanding to other indications in hematology and oncology within one year. Some demo videos can be found on: www.yiclinical. com. We’re solidifying a partnership with BMS — with their key stakeholders deeply embedded in our product development and testing.
www.BioNJ.org LIGHTNING PITCHES 6 Presenter: Daniel Weinstein, CEO & Co-Founder | [email protected] Lura Health enables non-invasive health monitoring with first-in-class salivary diagnostic wearable sensors. The company has created the world’s first non-invasive continuous health monitoring platform using saliva as a diagnostic fluid, which has the potential to improve clinical outcomes in chronic disease management. Applications include tooth decay, heart disease, chronic kidney disease and diabetes. Presenter: Jacob Boyle, CEO & Founder | [email protected] MARCo Health develops therapeutic social robots to improve mental health outcomes for adolescent and adult Patients struggling to get adequate care, while augmenting mental healthcare practices to reduce provider burnout and improve Patient engagement and risk management. We sell to three customer segments: D2C to parents of adolescents and young adults with anxiety or depressive disorders, school-based counseling systems and intensive outpatient groups. We have sold over 110 robots across six countries with over 10,000 active users through our robots and associated software. MARCo is in the presubmission stage of a 510(k) medical device application. Presenter: Sakina Dinani, M.D., Chief Medical Officer | [email protected] Navierre is a platform that enables users (healthcare consumers) to control all aspects of their health and actively manage their risks. The platform, presented to end-users as a web-app or mobile app, enables users to centralize their health information (records, insurance, wearable, medications), finding providers anywhere in the US by insurance, connect with caregivers and purchase from marketplace partners. The platform has a premium version that assess risks and recommends various solutions. We have brought a product to market and grown to acquire 35K users via B2B partnerships. We are raising our first Institutional round. Presenter: Vinodh Balaraman, CEO & Co-Founder | [email protected] During clinical trials, biopharmaceutical companies lack advance warning of upcoming trial events or trajectory changes, as such, they are forced to continue non-working trials and not take proactive actions on working trials. We are addressing this by building a Gen AI trial events prediction engine for sponsor stakeholders that delivers real-time insights to enable in-trial adjustments and improved execution. This will save time and cost and enable targeted drug development. We are currently building a foundation model for oncology, have completed POC for Patient clustering by SAE to demonstrate that the approach works and are in discussion with potential clients. Raising seed round.
LIGHTNING PITCHES www.BioNJ.org Presenter: Salvatore Campo, Co-Founder & CEO | [email protected] AI for enterprise clinical trial operations: • Tools • Clinical Copilot (say hi to Ally!) • Learning Experiences for any Clinical Trial Professional Presenter: Kirthika Parmeswaran, CEO & Founder | [email protected] Vital Start Health, a University of Pennsylvania start-up, has developed the first reproductive and maternity mental health platform using Virtual Reality for clinically guided care across pre-conception, birthing and postpartum. Our platform empowers moms and mental health practitioners to prevent and treat Perinatal Mood and Anxiety Disorders more effectively, equitably and faster using VR on-site at a clinic, health system or workplace and continuing at home virtually using either high-end VR or low-cost Mobile VR. We have won numerous awards, raised oversubscribed pre-seed funding, completed initial feasibility studies, launched platform, filed IP and are currently raising $2.5m seed. Presenter: Mathieu M. Petitjean, Ph.D., CEO | [email protected] PharmaNest is a Digital Pathology and AI company dedicated to developing and validating novels standards for the quantification of Fibrosis and Inflammation. PharmaNest’s Digital Pathology Biomarkers are calculated from conventional digital pathology images uploaded to its AWS-enabled FibroNest platform (FDA Approved). They have achieved a leadership position as a Drug Development Tool (FDA Biomarker Qualification on-going) for Liver Fibrosis (in NASH). Revenues grew 300% in 2023 and an active sales pipeline supports a double digit growth rate forecast. PharmaNest’s goal is to deploy FibroNest worldwide to assist pathologists in the evaluation and management of Patients with Fibrotic conditions ($4B market). Presenter: Donna Conroy, MS, Co-Founder & CEO | [email protected] Using AI, SciMar will reduce billions of pharmaceutical R&D costs and increase ROI by identifying and removing inefficiencies in strategic drug development using our products for Development Velocity™ (DV™). Removing inefficiencies will accelerate new therapies to market for longer market exclusivity, earlier revenue and better health outcomes. SciMar will prove this value hypothesis with our first customer contract beginning in 2025. 7
www.BioNJ.org 108 8 THANK YOU TO OUR SPONSORS DLA Piper is a global law firm with lawyers located in more than 40 countries throughout the Americas, Europe, the Middle East, Africa and Asia Pacific, positioning us to help clients with their legal needs around the world. We strive to be the leading global business law firm by delivering quality and value to our clients. We achieve this through practical and innovative legal solutions that help our clients succeed. We deliver consistent services across our platform of practices and sectors in all matters we undertake. Our clients, among them life sciences clients, range from multinational, Global 1000 and Fortune 500 enterprises to emerging companies. Morgan Stanley is a leading global financial services firm providing a wide range of investment banking, securities, financial services, wealth management and investment management services. For over 87 years, Morgan Stanley has served as a global leader in financial services advising clients on creating, trading. Managing and distributing capital — and we do so with a standard of excellence. At Morgan Stanley Wealth Management, exclusive access to vast resources, combined with our unique capabilities, gives us means to support your goals at every life stage. Our commitment to building, preserving and managing the wealth of our clients forms the foundation of everything we do. Teva Pharmaceuticals has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and innovative medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of innovative and biopharmaceutical products. Learn more at www.tevapharm.com.
www.BioNJ.org ATTENDEE LIST First Name Last Name Title Company Richard Algoo President IXB, Inc. Ashish Arte Co-Founder Surgeri, Inc. Albert Baker Corporate Director, LS Innov. and Tech Transfer Hackensack Meridian Health Vinodh Balaraman CEO and Co-Founder Kolate.AI Matt Balogh Head, Digital Marketing Melinta Therapeutics Jim Barrood Founder & CEO Innovation+ Michael Beaton Project Incubator BIOTECH XYZ Karl Beeson Vice President, Engineering Simphotek, Inc. Bob Bell Director, ERP Archer Insights Chris Bell Senior Director, Strategic Solutions C3 AI Najoua Borkadi Executive Director, Research Business Development Rutgers, The State University of New Jersey Jacob Boyle CEO MARCo Health, Inc. Kate Brashares CEO & Co-Founder Hello Therapeutics Daniela Brunner CIO & CTO Psychogenics Bridget Burke Chief Business Officer Slone Partners Sridhar Byrappa CEO Trial8, Inc. Salvatore Campo CEO & Founder tenXclinical Peter Chmiel Founder Cutting Edge Consulting John Clarke Managing General Partner Cardinal Partners Mary Cobb Patient Advocacy Consultant Global Genes Clayton Collins Vice President, Financial Advisor Morgan Stanley Lauren Conigliaro Portfolio Manager, Financial Planning Specialist Morgan Stanley Donna Conroy CEO & Founder SciMar ONE, Inc. Joe Cordasco Vice President, Sales & Marketing Synergistix Thomas Coughlin Owner Oncology Reference, LLC Philip Crowley Managing Partner Crowley Law, LLC Jason Daniels Medical Student Robert Wood Johnson Medical School Laszlo Danko Co-Founder Bioloupe Amy Day Director, IT UX and Change Management Genmab Pharma Jane Dela Cruz Office Manager Tech Council Ventures William DeStefano Vice President, Life Science Practice Marsh, Inc. Jeevan Duggempudi Partner, AI & Analytics IBM Tim Dyer Vice President, Facilities PTC Therapeutics, Inc. Michael Epstein Senior Vice President Cresa Global, Inc. Mee Eriksson CEO NeuroTechR3, Inc. Jose Espinoza CEO Move The Needle, LLC 9
www.BioNJ.org ATTENDEE LIST First Name Last Name Title Company Krista Fieselmann RWD Strategy Director Labcorp Robert Fiorentino Partner Marcum LLP Elizabeth Garner Chief Scientific Officer Ferring Pharmaceuticals, Inc. Allison Gassaro Sr. Director, Senior Corporate Counsel Kyowa Kirin, Inc. Mary George Vice President IXB Inc. Brent Glading Executive Director, Wealth Management Morgan Stanley Graystone Consulting Jim Gunton Managing Partner Tech Council Ventures Pablo Gurman Entrepreneur Maryam Hassimi Privacy Specialist Illumina, Inc. Evan Haupt CEO & Founder FloatR, Inc. Dixon Hayes Chief Investment Officer TRM Ventures Bethany Hills Partner DLA Piper, LLP Jake Hindelong Managing Director New Harbor Venture Partners Shravankumar Hiregoudar Consultant Slalom Brittany Hofferber Student Rutgers, RWJ Medical School John Houghton CEO & COO Consultant Guanghui Hu CEO NAKI Therapeutics Emily Iadanza Project Manager Onyx Management Group, LLC Malgorzata Jaremko Founder & CEO Gosia Genomics Inc. Karen Kainer Associate Director, Omnichannel Strategy & Operations Merck & Co. Steven Katz President Steven Katz & Associates, Inc. Nitin Khanna Founder & CEO Archer Insights Hirotaka Kimata Associate Director, Digital Healthcare Innovation Mitsubishi Tanabe Pharma America, Inc. Stephanie Koenig Senior Director, Content Strategy & Operations Syneos Health Mark Kolb Partner Tech Council Ventures Elena Korneeva Vice President, Corp & Institutional Solutions Morgan Stanley Suhas Krishna Vice President, Head, Product Management Digital Bristol Myers Squibb Company Rahul Krishnamoorthy Vice President, Business Development Impact Business Information Solutions, Inc. Alexander Kurian Founder Operatewise Philip Laut Vice President, Head, U.S. Sales, BD & Operations Iktos, Inc. Michael Lenahan Director, Private Equity VC Services RSM US, LLP Richard Lisi MD/MBA Candidate Robert Wood Johnson Medical School Kevin Lynch Executive Director Kyowa Kirin North America Will Ma Founder & CEO HopeAI, Inc., Andrew MacPherson Managing Director Revere Securities, LLC 10
www.BioNJ.org ATTENDEE LIST First Name Last Name Title Company Pooja Majmudar Director, Startup Banking Silicon Valley Bank John Maki CEO Bayesian Biotech Michael Malz Executive Director Morgan Stanley Greg Mayes President & CEO Reunion Neuroscience, Inc. Ryan McDevitt Senior Manager, US Policy & Public Affairs Pfizer Patricia McLain Trade Specialist U.S. Dept of Commerce Betsy McNeilly Executive Director, Financial Advisor Morgan Stanley Mittul Mehta CIO Tevogen Bio, Inc. Ernest Meyer Account Executive Medix Vincent Montalto Partner DLA Piper, LLP Eileen Morrissey Co-Founder & CEO MedifVu, LLC Sanjai Murali Founder & CEO JOGO Health, Inc. Lieven Nuyttens Principal Tri-Medix Tony O'Sullivan CEO IBIS Rob Ott Principal Consultant Ott Management Solutions, LLC Viji Padmanabhan Co-Founder Bioloupe Seth Painter Head, Life Sciences Partnerships OSTRO Greg Palko Vice President, North America Oncology Franchise Head KyowaKirin Kirthika Parmeswaran Founder & CEO Vital Start Health Mark Parsonson Executive Director, Pharma Services Investment Ban Morgan Stanley Laura Pereira Investment Director Flanders Investment & Trade Mathieu Petitjean CEO PHARMANEST Mary Potasek President Simphotek, Inc. Qinyin Qiu CSO NeuroTechR3, Inc. Ravi Raghunathan Partner CohnReznick, LLP Emilio Ragosa Partner & Managing Partner DLA Piper, LLP Sparsha Reddy Psychiatrist Sparsha S. Reddy MD PLLC Vicky Richards Chief Operating Officer The Alternative Board of Central NJ Paul Rittman Tricia Roman COO & Director of Client Services 325 Michael Rose President Vignetic, Inc. Anjan Roy Managing Director, Life Sciences AI & Data Deloitte Larry Samilow Co-Founder & Managing Partner Verve Group Consulting Anna Sandler Head, Digital Health Marketing Marketing Teva Pharmaceuticals Sameer Sethi Senior Vice President, Chief Data & Analytics Officer Hackensack Meridian Health 11
www.BioNJ.org ATTENDEE LIST First Name Last Name Title Company Tara Sharif Managing Director ThinkEquity Shantanu Sharma Founder Sharma Labs, Inc. Vik Sharma Founder MiraKare Elizabeth Sheeleigh Managing Director DLA Piper, LLP Judith Sheft Executive Director NJCSIT Richard Slawter Marketing Manager Innovative Development Vincent Smeraglia Executive Director Rutgers University Monica Smith Founder & CEO Marketsmith, Inc. Daniel Spring Senior Research Associate Ashton Tweed, LTD Aaditya Srivastava Product Lead tenXclinical Edward Steimakh CFO & COO OptimizeRx Douglas Stewart Senior Principal Slalom Erone Stewart Executive Director Vignetic, Inc. John Talbot Client Development Executive DLA Piper, LLP Nicholas Tardy Financial Advisor, Equity Plan Advisor Morgan Stanley Mark Theeuwes COO Reunion Neuroscience, Inc. Danny Tobey Partner, Chair, AI and Data Analytics DLA Piper, LLP Katie Tolkacz Associate Director Commercial Regulatory & Innovation IvericBio, an Astellas Company Vince Traylor Director of Sales & Partnerships - US Mkt NuraLogix Matthew Van Dusen CEO Literate AI Sarah-Beth Vaughn Senior Life Science Officer NJEDA Jared Vizzi Director, Oncology Marketing Kyowa Kirin Wayne Weiner Managing Director Pharmatech Solutions, LLC Natalie Weinrauch Consultant, Strategy & Analytics Deloitte Consulting, LLP Daniel Weinstein CEO Lura Health Paul Xu Business Development Specialist NAROS Mark Youssef CEO NavXbio 12